COVID-19 infection is linked to a measurably higher risk of developing new allergic conditions, including asthma, allergic rhinitis, and other allergic diseases. A multinational study across South Korea, Japan, and the United Kingdom found that the overall risk of new allergic disease rose by about 20 percent after a COVID-19 diagnosis, with asthma risk more than doubling. The connection persisted for at least six months and grew stronger with more severe illness. What makes this especially interesting is that the mechanisms appear to go well beyond a simple immune overreaction, involving everything from mast cell misbehavior to lasting changes in the gut microbiome.
What the Large Studies Actually Show
The most comprehensive look at this question comes from a multinational cohort study published in Nature Communications that tracked hundreds of thousands of people in three countries. After adjusting for a wide range of confounding factors, the researchers found that SARS-CoV-2 infection was associated with a roughly 20 percent increase in the hazard of developing any new allergic disease. The increase was sharpest for asthma, where the risk more than doubled, and for allergic rhinitis, which rose by about 23 percent. The study did not find a statistically significant increase in atopic dermatitis or food allergy.1Nature Communications. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK
A separate propensity-matched cohort study of both children and adults found that COVID-19 infection was tied to significantly higher rates of all six allergic conditions examined in the full cohort. In children specifically, every condition except food allergy was significantly associated with prior infection. Even among active-duty military personnel, a group that tends to be healthier than the general population, asthma and rhinoconjunctivitis were significantly linked to COVID-19 infection.2PubMed. Post-COVID-19 onset of allergic conditions in a propensity-matched cohort of children and adults
These are not fringe findings from a single research group. The fact that the pattern shows up in different countries, across multiple age groups, and in populations with very different healthcare systems makes the signal hard to dismiss. That said, observational studies cannot prove that COVID directly caused anyone’s new allergy. People who catch COVID may differ from those who do not in ways that influence allergy risk, even after statistical adjustment. Still, the consistency and the dose-response relationship with disease severity strongly suggest something real is going on.
How COVID Might Rewire Your Immune System Toward Allergy
The immune system is not a single on-off switch. It has multiple modes of defense, and the type of response it mounts matters enormously. Allergies happen when a branch of immunity geared toward fighting parasites starts overreacting to harmless things like pollen, pet dander, or certain foods. COVID-19 appears to nudge the immune system toward that allergy-prone state through several overlapping pathways.
When SARS-CoV-2 damages the cells lining the airways and gut, those injured cells release alarm signals, specifically a group of molecules called alarmins. These alarmins promote the expansion of immune cells that drive allergic inflammation and push the broader immune environment toward what researchers describe as a Th2-biased state, the same profile that underlies hay fever, asthma, and eczema. This is not just a temporary shift. Evidence suggests the virus can leave what amount to epigenetic “scars” on immune cells, reprogramming even the stem cells that generate new immune cells so that the bias persists long after the infection clears.3PubMed Central. Immunological Mechanisms Underlying Allergy Predisposition After SARS-CoV-2 Infection in Children
At the same time, COVID appears to impair the regulatory arm of the immune system, the cells whose job is to tell the rest of the immune system to stand down when there is no real threat. When regulatory function drops, the threshold for triggering an allergic reaction can drop with it. The result is an immune system that is both more primed to react in an allergic fashion and less able to rein itself in.3PubMed Central. Immunological Mechanisms Underlying Allergy Predisposition After SARS-CoV-2 Infection in Children
Mast Cells and IgE Gone Rogue
If you have ever had an allergic reaction, you have felt mast cells at work. These are the cells that dump histamine and other inflammatory chemicals into your tissues, causing the swelling, itching, sneezing, and flushing that characterize allergies. In long COVID, researchers have found that mast cells can enter an abnormally activated state, releasing inflammatory chemicals far more readily than they should.4PubMed Central. Immunological dysfunction and mast cell activation syndrome in long COVID
This activated mast cell state helps explain why some people with long COVID report a bewildering range of new sensitivities: flushing after eating certain foods, hives after mild exercise, or sudden intolerance to products they had used for years. Whether this constitutes a true new allergy or something more like mast cell activation syndrome, where the cells are hyperreactive without a specific allergic trigger, remains a matter of active investigation. For the person experiencing it, the distinction can feel academic; the symptoms are real and disruptive either way.
Adding another layer, SARS-CoV-2 infection appears to trigger an unexpected IgE antibody response directed against the virus’s own proteins. IgE is the antibody class most associated with allergic reactions. Researchers have observed IgE antibodies targeting the receptor-binding domain and other SARS-CoV-2 proteins after both natural infection and vaccination. The simultaneous presence of IgE alongside other antibody types like IgG4 suggests the virus may provoke an allergic-like immune response, possibly as a way of evading normal immune defenses.5PubMed Central. High Free IgE and Mast Cell Activation in Long COVID: Mechanisms of Persistent Immune Dysregulation
Whether this virus-directed IgE then primes the immune system to produce IgE against unrelated allergens is still being studied, but the elevated baseline of IgE and mast cell activation provides a plausible bridge between COVID infection and new clinical allergies.
The Gut Connection
Your gut microbiome, the trillions of bacteria living in your intestines, plays a surprisingly large role in keeping the immune system calibrated. A diverse, healthy microbiome helps train immune cells to tolerate harmless substances rather than attack them. COVID-19 can disrupt this balance in ways that persist well beyond the acute illness.
Research on post-COVID patients has shown lasting changes in gut bacteria: less microbial diversity overall, more opportunistic and potentially harmful species, and a decline in the beneficial bacteria that support immune balance and metabolic health.6The Innovation Medicine. The gut microbiome in post-COVID syndrome patients Severe cases, especially those involving pneumonia, tend to produce the most pronounced shifts. One study found that post-COVID syndrome is marked by a gut microbiome skewed toward a pro-inflammatory profile, along with a complex web of elevated inflammatory signaling molecules.7PubMed Central. Gut Microbiome and Cytokine Profiles in Post-COVID Syndrome
This matters for allergy risk because the gut microbiome is one of the main regulators of immune tolerance. When the bacterial community shifts toward inflammation-promoting species, the immune system gets fewer of the signals that keep it from overreacting. This is the same general principle behind the “hygiene hypothesis” that has been discussed in allergy research for decades, but COVID seems capable of producing the microbiome disruption much more acutely and profoundly than typical lifestyle factors.
Severity Matters, and Vaccination Appears Protective
One of the more striking findings is that the risk of developing post-COVID allergies scales with how sick you were. The multinational cohort study found that moderate-to-severe COVID-19 carried a 48 percent increase in risk of overall allergic disease, compared to a 14 percent increase for mild infections.1Nature Communications. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK This dose-response pattern strengthens the case that the infection itself is driving the allergy risk, since more immune disruption during a severe infection would logically lead to a larger downstream effect.
Vaccination tells an equally important story. In the same study, people who received at least two doses of a COVID-19 vaccine before infection showed a significantly lower risk of developing new allergic conditions. In fact, the risk of overall allergic disease and its subtypes was no longer significantly elevated compared to uninfected controls when someone had been vaccinated at least twice.1Nature Communications. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK This does not mean vaccines eliminate allergy risk, but it suggests that reducing the severity and duration of infection through vaccination may prevent the deep immune disruption that leads to new allergies. It is one of the most practical takeaways from the research so far.
Not Every New Sensitivity Is a True Allergy
If you have noticed new sneezing, congestion, or nasal drip since having COVID, it is worth knowing that not all of those symptoms reflect a conventional allergic mechanism. Vasomotor rhinitis, a condition where the nasal passages become chronically inflamed and overly sensitive without an identifiable allergen trigger, has been documented in post-COVID patients. Research suggests this form of rhinitis involves nonspecific histamine release and chronic eosinophilic inflammation, driven in part by oxidative stress that depletes the protective capacity of nitric oxide in the nasal passages.8Journal of Otorhinolaryngology. Features of Vasomotor Rhinitis (VMR) in Patients with a History of COVID-19 Infection
In plain terms, this means your nose might be running, congested, or dripping constantly after COVID, but a standard allergy test could come back completely normal because there is no specific allergen causing the problem. The nasal lining is simply stuck in a state of irritation. Temperature changes, strong scents, exercise, and even eating spicy food can set it off. This is frustrating for patients who feel certain they have “become allergic to something” and want a clear answer, but it also matters for treatment. Vasomotor rhinitis does not respond well to the same medications used for classic allergies and often requires a different approach, such as nasal anticholinergic sprays rather than antihistamines alone.
Similarly, the mast cell activation syndrome described earlier can mimic food allergies, drug allergies, and environmental allergies without showing up on standard IgE-based allergy tests. If you are experiencing unexplained flushing, hives, or gastrointestinal symptoms after COVID, the underlying issue may be overactive mast cells rather than a specific new allergy, and that distinction matters when deciding how to treat it.
When Antihistamines Actually Help
For people experiencing allergy-like symptoms tied to long COVID, one encouraging finding is that antihistamines seem to make a genuine difference. A study examining long-COVID patients treated with antihistamines found that symptoms completely disappeared in about 29 percent of treated patients. Every symptom measured showed significant improvement in the treatment group, while untreated controls saw no meaningful change.9PubMed Central. Antihistamines improve cardiovascular manifestations and other symptoms of long-COVID attributed to mast cell activation
This is noteworthy because antihistamines are cheap, widely available, and carry a low side-effect burden. Some clinicians treating long COVID have adopted a strategy of combining a first-generation H1 blocker (like the common over-the-counter options used for seasonal allergies) with an H2 blocker (typically used for heartburn). The rationale is that histamine receptors exist throughout the body, not just in the nose and eyes, so blocking multiple receptor types can address a wider range of symptoms, from nasal congestion and hives to palpitations and GI distress.
This does not mean antihistamines are a cure for long COVID or that every post-COVID symptom is histamine-driven. But for the subset of patients whose complaints look allergy-like, a simple antihistamine trial is a reasonable and low-risk first step, and the evidence supports it more clearly than many other long-COVID interventions studied so far.
Getting a Proper Diagnosis
One of the trickiest aspects of post-COVID allergic symptoms is sorting out what is actually happening. Are you dealing with a genuine new allergy with a specific trigger? Mast cell overactivation without a clear trigger? Vasomotor rhinitis from nerve and tissue damage? Or something else entirely, like long-COVID fatigue or anxiety that happens to produce overlapping symptoms?
Standard allergy workup still applies. Skin prick tests, blood tests for specific IgE antibodies, and in some cases provocation tests can identify or rule out true new allergies. For patients experiencing drug or vaccine-related allergic concerns, a step-by-step approach including allergy history, skin testing, and graded exposure has been shown to be both effective and reassuring.10PubMed Central. SARS-CoV-2 and allergy – what have we learned after two and a half years? If those tests are negative but symptoms persist, the conversation should shift toward mast cell disorders or neurogenic inflammation rather than continuing to hunt for a specific allergen.
If you already had allergies before COVID, pay attention to whether your existing allergies have worsened or whether entirely new triggers have appeared. Both patterns have been reported, and they can coexist. Someone with a longstanding spring pollen allergy might find that their seasonal symptoms are worse than before, while also developing new reactions to a food they previously tolerated. These may involve different mechanisms and may need different management strategies.
Children Deserve a Separate Conversation
The pediatric data paints a particularly clear picture. In the propensity-matched cohort study, children who had COVID showed significantly higher rates of developing all examined allergic conditions except food allergy.2PubMed. Post-COVID-19 onset of allergic conditions in a propensity-matched cohort of children and adults This is concerning because childhood is already a period of rapid immune system development, and disruptions during this window may have longer-lasting consequences than similar disruptions in adults.
The mechanistic picture in children appears to follow the same broad strokes as in adults: airway and gut lining damage, alarmin release, Th2 polarization, epigenetic reprogramming, and disrupted regulatory T-cell function.3PubMed Central. Immunological Mechanisms Underlying Allergy Predisposition After SARS-CoV-2 Infection in Children But the developing immune system may be more susceptible to this kind of reprogramming, which raises questions about whether children infected with COVID-19 might carry an elevated allergy burden for years or even decades. That research is still being done; the follow-up periods in existing studies are relatively short.
For parents, the practical implication is straightforward. If your child develops new allergy symptoms, such as wheezing, chronic runny nose, eczema, or suspected food reactions, in the months following a COVID infection, it is worth mentioning the timeline to your pediatrician. A post-COVID onset does not change the immediate treatment, but it may affect how aggressively clinicians choose to monitor and manage the condition over time.
Allergen Immunotherapy and COVID
If you were already receiving allergen immunotherapy (allergy shots or sublingual tablets) before catching COVID, or you are considering starting after developing new allergies post-COVID, the safety data is reassuring. A study of over 400 allergic rhinitis patients, roughly half of whom were receiving allergen immunotherapy, found no significant difference in the rates of COVID-19 infection, pneumonia, or hospitalization between those on immunotherapy and those who were not.11The European Research Journal. Safety of allergen immunotherapy in patients with SARS-CoV-2 infection
This addresses a concern that many allergy patients had during the pandemic: would immunotherapy, which deliberately stimulates the immune system, make COVID worse or increase susceptibility? The available evidence says no. Immunotherapy works by building tolerance to specific allergens, a different arm of immune modulation than antiviral defense. For patients who develop genuine new IgE-mediated allergies after COVID, immunotherapy remains a viable long-term treatment option, particularly for respiratory allergies like hay fever and allergic asthma where it has the best track record.
The Risk Fades but Does Not Vanish Quickly
The multinational cohort data shows that the elevated risk of new allergic conditions gradually decreased over time after COVID-19 infection but persisted throughout the follow-up period, which extended to at least six months.1Nature Communications. Incident allergic diseases in post-COVID-19 condition: multinational cohort studies from South Korea, Japan and the UK This means the first six months after infection appear to be the highest-risk window, but the immune system does not snap back to its pre-infection baseline immediately.
Whether the risk eventually returns to normal or leaves a permanent mark is still unclear. The epigenetic changes and stem cell reprogramming described in mechanistic studies suggest that at least some immune alterations could be long-lasting. On the other hand, the gut microbiome is somewhat resilient and can recover diversity over time, particularly with dietary changes and, in some cases, targeted interventions. The practical message is that new allergy-like symptoms appearing within the first several months after COVID deserve prompt attention, but symptoms that emerge a year or more later are less likely to be directly attributable to the infection.
For those already dealing with post-COVID allergies, the combination of proper diagnosis, antihistamine therapy when appropriate, and standard allergy management remains the most evidence-supported approach. Given how recently this phenomenon has been recognized, it is worth keeping in mind that treatment recommendations will likely evolve as longer-term data becomes available and as researchers gain a clearer picture of which immune changes are reversible and which are not.